CA3072455A1 - Pyruvate kinase modulators and use thereof - Google Patents

Pyruvate kinase modulators and use thereof Download PDF

Info

Publication number
CA3072455A1
CA3072455A1 CA3072455A CA3072455A CA3072455A1 CA 3072455 A1 CA3072455 A1 CA 3072455A1 CA 3072455 A CA3072455 A CA 3072455A CA 3072455 A CA3072455 A CA 3072455A CA 3072455 A1 CA3072455 A1 CA 3072455A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
protecting group
instance
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072455A
Other languages
English (en)
French (fr)
Inventor
Giovanni Cianchetta
Charles KUNG
Tao Liu
Anil Kumar PADYANA
Zhihua Sui
Zhenwei CAI
Dawei Cui
Jingjing Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CA3072455A1 publication Critical patent/CA3072455A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3072455A 2017-08-15 2018-08-15 Pyruvate kinase modulators and use thereof Pending CA3072455A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
CNPCT/CN2017/097496 2017-08-15
US201862673526P 2018-05-18 2018-05-18
US201862673533P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000129 WO2019035865A1 (en) 2017-08-15 2018-08-15 MODULATORS OF PYRUVATE KINASE AND THEIR USE

Publications (1)

Publication Number Publication Date
CA3072455A1 true CA3072455A1 (en) 2019-02-21

Family

ID=63524352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072455A Pending CA3072455A1 (en) 2017-08-15 2018-08-15 Pyruvate kinase modulators and use thereof

Country Status (34)

Country Link
US (8) US11464775B2 (https=)
EP (4) EP3668512B1 (https=)
JP (5) JP7301040B2 (https=)
KR (3) KR102717594B1 (https=)
CN (2) CN111032046B (https=)
AU (4) AU2018316587B2 (https=)
BR (1) BR112020003254A2 (https=)
CA (1) CA3072455A1 (https=)
CL (1) CL2020000375A1 (https=)
CO (2) CO2020002961A2 (https=)
CR (1) CR20200123A (https=)
CY (1) CY1124953T1 (https=)
DK (2) DK3668513T3 (https=)
EC (1) ECSP20018487A (https=)
ES (3) ES2905100T3 (https=)
FI (1) FI3668512T3 (https=)
HR (2) HRP20230452T1 (https=)
HU (2) HUE057178T2 (https=)
IL (3) IL272599B (https=)
LT (2) LT3668512T (https=)
MD (1) MD3668513T2 (https=)
MX (2) MX2020001833A (https=)
MY (1) MY204421A (https=)
PE (1) PE20200724A1 (https=)
PH (1) PH12020500343B1 (https=)
PL (2) PL3668512T3 (https=)
PT (2) PT3668512T (https=)
RS (2) RS62871B1 (https=)
SG (2) SG11202001353PA (https=)
SI (2) SI3668512T1 (https=)
SM (2) SMT202200023T1 (https=)
TW (3) TWI790271B (https=)
UA (1) UA126292C2 (https=)
WO (3) WO2019035863A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
DK3668513T3 (da) 2017-08-15 2022-01-10 Agios Pharmaceuticals Inc Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
EP3924056A1 (en) * 2019-02-13 2021-12-22 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
JP7517337B2 (ja) * 2019-06-26 2024-07-17 日産化学株式会社 電荷輸送性ワニス
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
AU2021311597A1 (en) * 2020-07-21 2023-02-02 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
WO2023091414A1 (en) * 2021-11-16 2023-05-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
CN121263419A (zh) 2023-05-15 2026-01-02 安吉奥斯医药品有限公司 2-((1h-吡唑-3-基)甲基)-6-((6-氨基吡啶-2-基)甲基)-4-甲基-4,6-二氢-5h-噻唑并[5',4':4,5]吡咯并[2,3-d]哒嗪-5-酮的结晶盐或无定形形式
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
TW202539675A (zh) 2024-03-27 2025-10-16 美商阿吉歐斯製藥公司 Ｐｋ活化劑在治療鐮狀細胞疾病中之用途
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
SK1512002A3 (en) 1999-07-30 2002-11-06 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MXPA02002319A (es) 1999-09-04 2002-07-30 Astrazeneca Ab Derivados 2-hidroxi-2-metil-3,3,3-trifluoropropanamida con n-fenilo susbtituido que elevan la actividad de la deshidrogenasa de piruvato.
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
AU2009303335B2 (en) 2008-10-09 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
WO2010118063A2 (en) * 2009-04-06 2010-10-14 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
PE20140421A1 (es) 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151448A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
SG194697A1 (en) * 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
ES2746558T3 (es) 2011-05-03 2020-03-06 Agios Pharmaceuticals Inc Activadores de piruvato cinasa R para uso en terapia
EP3372230B1 (en) 2011-05-03 2020-08-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2013012915A1 (en) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
KR20150080619A (ko) * 2012-11-08 2015-07-09 아지오스 파마슈티컬스 아이엔씨. 치료적 화합물 및 조성물
US9745304B2 (en) * 2013-01-30 2017-08-29 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as MKNK-1 kinase inhibitors
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
NZ760129A (en) 2017-07-07 2025-12-19 Inflazome Ltd Novel sulfonamide carboxamide compounds
DK3668513T3 (da) 2017-08-15 2022-01-10 Agios Pharmaceuticals Inc Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
EP3924056A1 (en) * 2019-02-13 2021-12-22 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
PL3668512T3 (pl) 2023-06-19
CN111032045B (zh) 2023-08-15
JP7301040B2 (ja) 2023-06-30
IL292530A (en) 2022-06-01
SMT202300146T1 (it) 2023-07-20
JP2020531432A (ja) 2020-11-05
CO2020002959A2 (es) 2020-04-13
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
TW201919631A (zh) 2019-06-01
JP7530453B2 (ja) 2024-08-07
SG11202001262QA (en) 2020-03-30
WO2019035864A1 (en) 2019-02-21
JP2024147805A (ja) 2024-10-16
US11464775B2 (en) 2022-10-11
EP3668512A1 (en) 2020-06-24
JP2023052478A (ja) 2023-04-11
DK3668512T3 (da) 2023-05-22
AU2018316588B2 (en) 2023-02-02
US20220395503A1 (en) 2022-12-15
HRP20220039T1 (hr) 2022-04-15
TW202323258A (zh) 2023-06-16
FI3668512T3 (fi) 2023-05-12
KR102764124B1 (ko) 2025-02-05
CN111032046A (zh) 2020-04-17
US20200206225A1 (en) 2020-07-02
JP2020531443A (ja) 2020-11-05
SI3668513T1 (sl) 2022-04-29
EP3668881A1 (en) 2020-06-24
TW201920203A (zh) 2019-06-01
TWI790271B (zh) 2023-01-21
KR20230127364A (ko) 2023-08-31
US11364240B2 (en) 2022-06-21
LT3668513T (lt) 2022-03-25
ECSP20018487A (es) 2020-05-29
EP3668513B1 (en) 2021-11-10
PE20200724A1 (es) 2020-07-21
SI3668512T1 (sl) 2023-06-30
CY1124953T1 (el) 2023-01-05
UA126292C2 (uk) 2022-09-14
WO2019035865A8 (en) 2019-03-28
SG11202001353PA (en) 2020-03-30
AU2023202772A1 (en) 2023-05-18
WO2019035865A1 (en) 2019-02-21
ES2905100T3 (es) 2022-04-07
US20210077490A1 (en) 2021-03-18
EP3668881B1 (en) 2023-10-04
CN117186119A (zh) 2023-12-08
US12133853B2 (en) 2024-11-05
DK3668513T3 (da) 2022-01-10
SMT202200023T1 (it) 2022-03-21
PH12020500343A1 (en) 2021-02-08
EP3668512B1 (en) 2023-02-15
US20220233541A1 (en) 2022-07-28
RS62871B1 (sr) 2022-02-28
IL272597B (en) 2022-06-01
US11590132B2 (en) 2023-02-28
HUE057178T2 (hu) 2022-04-28
US20250144093A1 (en) 2025-05-08
AU2023202772B2 (en) 2024-05-16
IL272599A (en) 2020-03-31
MX2020001832A (es) 2020-07-22
JP7275107B2 (ja) 2023-05-17
PL3668513T3 (pl) 2022-03-21
EP3668513A1 (en) 2020-06-24
RS64221B1 (sr) 2023-06-30
EP4026838A1 (en) 2022-07-13
PH12020500343B1 (en) 2024-02-21
US20200207785A1 (en) 2020-07-02
LT3668512T (lt) 2023-06-12
AU2024205818A1 (en) 2024-09-05
US11040036B2 (en) 2021-06-22
IL272597A (en) 2020-03-31
JP2023027276A (ja) 2023-03-01
US11872225B2 (en) 2024-01-16
US20230226055A1 (en) 2023-07-20
WO2019035863A1 (en) 2019-02-21
RU2020110573A3 (https=) 2021-12-24
AU2018316587B2 (en) 2023-05-11
PT3668512T (pt) 2023-05-22
MD3668513T2 (ro) 2022-04-30
CR20200123A (es) 2020-06-29
US11957680B2 (en) 2024-04-16
BR112020003254A2 (pt) 2020-10-27
BR112020003262A2 (pt) 2020-09-01
RU2020110573A (ru) 2021-09-16
MY204421A (en) 2024-08-28
KR20200054200A (ko) 2020-05-19
MX2020001833A (es) 2020-07-22
KR102717594B1 (ko) 2024-10-14
KR102642408B1 (ko) 2024-02-28
CO2020002961A2 (es) 2020-04-13
ES2966825T3 (es) 2024-04-24
CL2020000375A1 (es) 2020-12-11
CN111032046B (zh) 2023-09-26
AU2018316588A1 (en) 2020-02-20
KR20200054199A (ko) 2020-05-19
AU2018316587A1 (en) 2020-02-20
US20210130371A1 (en) 2021-05-06
CN111032045A (zh) 2020-04-17
WO2019035863A8 (en) 2019-03-28
HUE061910T2 (hu) 2023-08-28
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
WO2019035864A8 (en) 2019-03-28
TWI796353B (zh) 2023-03-21
IL292530B2 (en) 2023-06-01
IL272599B (en) 2022-08-01
ES2944545T3 (es) 2023-06-22

Similar Documents

Publication Publication Date Title
US11872225B2 (en) Pyruvate kinase modulators and use thereof
CN108602776B (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN112236429B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
CA2971640C (en) Cot modulators and methods of use thereof
CA3129829A1 (en) Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
CN107108561A (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN112930213A (zh) 用作布鲁顿酪氨酸激酶(btk)的可逆抑制剂的稠合咪唑并吡啶
RU2797518C2 (ru) Модуляторы пируваткиназы и их применение
HK40030322A (en) Pyruvate kinase modulators and use thereof
HK40030322B (en) Pyruvate kinase modulators and use thereof
HK40043591A (en) Heteroaryl compounds as type ii irak inhibitors and uses thereof
HK1242303A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
HK1247918A1 (en) Macrocyclic compounds as irak1/4 inhibitors and uses thereof
HK1242303B (zh) 用作irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250213

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250213

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250403

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250403

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250721

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250806

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250806

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808